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Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cancer. One of the processes
disturbed in this cancer type is alternative splicing, although phenomena underlying these disturbances remain unknown.
Alternative splicing consists of selective removal of introns and joining of residual exons of the primary transcript, to
produce mRNA molecules of different sequence. Splicing aberrations may lead to tumoral transformation due to synthesis
of impaired splice variants with oncogenic potential. In this paper we hypothesized that disturbed alternative splicing in
ccRCC may result from improper expression of splicing factors, mediators of splicing reactions.
Methodology/Principal Findings: Using real-time PCR and Western-blot analysis we analyzed expression of seven splicing
factors belonging to SR proteins family (SF2/ASF, SC35, SRp20, SRp75, SRp40, SRp55 and 9G8), and one non-SR factor,
hnRNP A1 (heterogeneous nuclear ribonucleoprotein A1) in 38 pairs of tumor-control ccRCC samples. Moreover, we
analyzed splicing patterns of five genes involved in carcinogenesis and partially regulated by analyzed splicing factors: RON,
CEACAM1, Rac1, Caspase-9, and GLI1.
Conclusions/Significance: We found that the mRNA expression of splicing factors was disturbed in tumors when compared
to paired controls, similarly as levels of SF2/ASF and hnRNP A1 proteins. The correlation coefficients between expression
levels of specific splicing factors were increased in tumor samples. Moreover, alternative splicing of five analyzed genes was
also disturbed in ccRCC samples and splicing pattern of two of them, Caspase-9 and CEACAM1 correlated with expression of
SF2/ASF in tumors. We conclude that disturbed expression of splicing factors in ccRCC may possibly lead to impaired
alternative splicing of genes regulating tumor growth and this way contribute to the process of carcinogenesis.
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Introduction
Renal cell carcinoma (RCC) is the most common solid lesion of
the kidney and represents ,3% of all human malignancies. Each
year in Europe about 40 000 new cases of RCC are diagnosed and
approximately 20 000 patients die of the disease [1]. The vast
majority (80%) of RCC cases are histologically classified as clear
cell renal cell carcinomas (ccRCC), originating from proximal
tubules of the kidney. The molecular basis of ccRCC is not fully
understood. Although several molecular markers have been
proposed, neither of them has been approved for routine clinical
use [2].
One of the cellular processes, often disturbed in cancers, is
alternative splicing, the process of selective removal of introns and
joining of residual exons, in which mRNA molecules of various
sequences are produced. Aberrant alternative splicing may lead to
tumoral transformation [3]. Impaired alternative splicing of
several genes was also reported in ccRCC. For instance, in our
previous work we found ccRCC-specific imbalanced expression of
type 1 iodothyroine deiodinase (DIO1) splicing variants [4,5] and
untranslated regions of thyroid hormone receptor TRb1 [6].
Several other reports showing ccRCC-specific disturbances of
alternative splicing include alterations in mRNA processing of
Mcl-1 [7], TCF-4 [8], survivin [9], and OGG1 [10]. Abnormally
spliced variants of genes described above are rarely effects of
mutations in genes coding for spliced transcripts and the sources of
disturbances in alternative splicing are usually unknown.
Alternative splicing is a complicated process, involving a
significant number of proteins including splicing factors called
serine-arginine rich proteins (SR proteins) [11]. The family of SR
proteins consists of at least twenty members of which seven: SF2/
ASF (encoded by gene: SFRS1), SC35 (gene: SFRS2), SRp20 (gene:
SFRS3), SRp75 (gene: SFRS4), SRp40 (gene: SFRS5), SRp55
(SFRS6), and 9G8 (SFRS7) constitute the group of ‘‘classical’’ SR
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located in exons (ESEs, exonic splicing enhancers) or in introns
(ISEs, intronic splicing enhancers). Binding of SR proteins to
splicing enhancers promotes exon inclusion. The splicing reaction is
also regulated by a large number of non-SR factors, such as
hnRNPs (heterogeneous nuclear ribonucleoproteins) which mainly
bind to sequences of splicing silencers and act as splicing repressors
[12]. Thus, the final result of alternative splicing is an effect of the
concert action of antagonistically acting splicing factors. One pair of
splicing factors exhibiting opposite activities is SF2/ASF (an SR
protein) and hnRNP A1 (heterogeneous nuclear ribonucleoprotein
A1; a non-SR protein) [13]. Excess of SF2/ASF promotes proximal
59 splice site selection while of hnRNP A1 favours distal 59 splice
site. Specific members of SR family may also act antagonistically
(e.g. SF2/ASF andSRp20 [14], orSF2/ASF and SC35 [15]).Thus,
relative levels of specific splicing factors contribute to regulation of
alternative splicing, specific for tissue type and developmental stage.
It is known that disturbances in alternative splicing may
contribute to carcinogenesis due to production of tumor-
suppressive or oncogenic variants of gene transcripts, affecting
proliferation, cell motility, and apoptosis susceptibility [16].
Improperly spliced transcript variants may also serve as tumor
biomarkers [17]. The growing body of evidence suggests that
splicing factors may be directly involved in the process of
carcinogenesis, acting as proto-oncogenes [18] or regulating
splicing and activity of proto-oncogenes [19], tumor suppressors
[18] and apoptosis regulators [20]. Disturbed expression of
splicing factors was reported in several types of cancers [11]. In
our recent paper we showed that the expression of two splicing
factors, SF2/ASF and hnRNP A1 is disturbed in ccRCC [4] but to
our knowledge the expression of splicing factors as a group had
never been analyzed in ccRCC.
In this paper we hypothesized that the observed disturbances of
alternative splicing in ccRCC may be a consequence of changes in
expression of splicing factors, in particular, of aberrations of
quantitative relations between them. To address this problem, we
analyzed expression of seven classical splicing factors: SF2/ASF,
SC35, SRp20, SRp75, SRp40, SRp55, 9G8 and a non-SR factor,
hnRNP A1. In addition, to investigate the consequences of
disturbed expression of splicing factors, we analyzed existence and
expression of transcripts of five genes involved in tumorigenesis,
that are known to be alternatively spliced and partially regulated
by the analyzed splicing factors. We found that the expression of
splicing factors as well as alternative splicing of analyzed genes
were disturbed in majority of analyzed tissue samples. We
conclude that disturbed expression of splicing factors in ccRCC
may possibly lead to impaired alternative splicing of genes




Tissue samples were obtained from unilateral nephrectomies
performed on patients with clear cell renal cell cancer (38 patients)
with permission of the Ethical Committee of Human Studies (The
Medical Centre of Postgraduate Education). Samples were divided
intotwo groups: cancer tissues (n=38, T) and controltissues (paired
normal tissue from the opposite pole of the malignant kidney with
no histological evidence of tumor; n=38, C). Clear cell renal cell
cancer was diagnosed by histology according to WHO criteria [21].
Tumors were divided into three groups, depending on the grade of
differentiation: G1 (well differentiated), G2 (intermediate grade of
differentiation), G3 (poorly differentiated cancers).
RNA isolation
Total cellular RNA was isolated from ,100 mg of frozen tissue
using GeneMATRIX Universal RNA Purification Kit (EURx,
Gdansk, Poland), according to the manufacturer’s protocol.
Reverse transcription
600 ng of total RNA was reverse transcribed using Rever-
tAidTM H Minus First Strand cDNA Synthesis Kit (Fermentas,
Vilnius, Lithuania) and oligo-dT primers according to the
manufacturer’s protocol. For subsequent PCR analysis 1 ul of
cDNA was used. For real time PCR reactions 1 ul of 5x diluted
cDNA was taken.
PCR analysis of alternative splicing
PCR reaction was performed on 1 ml of 5x diluted cDNA using
Perpetual OptiTaq DNA Polymerase HOT START (EURx,
Gdansk, Poland) under conditions 95uC, 10 min. (initial denatur-
ation), followed by 35 cycles: [95uC, 30 s; 58uC, 30 s; 72uC, 30 s],
final elongation: 61uC, 10 min. Sequences of specific primers
(Table S1) were taken from the previously published reports for:
RON [19], Caspase-9 [22], CEACAM-1 [23], Rac1 [24], and
GLI1 [25]. The PCR products were electrophoresed in 1–2%
agarose gel stained with ethidium bromide.
Real-time PCR
Semi-quantitative real-time PCR was performed using Light-
CyclerH 480 DNA SYBR Green I Master (Roche Diagnostics,
Mannheim, Germany) in triplicate according to manufacturer’s
protocol. Sequences of the primers are shown in Table S2.
Conditions for real-time PCR were as follows: initial denaturation:
95uC, 10 min., 45 cycles: (95uC, 15 s, 57uC, 15 s; 72uC, 15 s);
followed by melting curve analysis: (95uC, 5 min; 65uC, 1 min;
continuous reading of fluorescence from 65uCt o9 7 uC with
0.11uC/s ramp rate and 5 acquisitions per each uC). Results were
normalized to expression of 18sRNA host-gene RN18S1. The
stability of expression of 18sRNA was validated and confirmed in
initial pre-analysis of 32 pairs of control and tumor samples by
comparison with ACTB expression (Figure S1). The ACTB
primers were published elsewhere [6].
Protein extraction and Western blot analysis
For Western analysis, twelve representative pairs of tumor and
control samples were taken. Tissue samples were homogenized in
a buffer containing 150 mM NaCl, 1% Triton X-100, 50 mM
Tris-HCl pH 8.0, protease inhibitor cocktail (Sigma-Aldrich, Saint
Louis, MO), and 0.5 mM PMSF. The homogenate was incubated
with shaking for 2 hours at 4uC and centrifuged at 12,000 rpm for
20 min, at 4uC. The obtained supernatant was used for protein
concentration analysis with Thermo Scientific Pierce BCA Protein
Assay (Pierce Biotechnology, Rockford, IL) according to standard
protocol. The protein extracts were divided into 30 ml aliquots and
stored at 270uC.
For SF2/ASF Western blotting, 30 mg of protein extract was
resolved by 10% SDS-PAGE. After electrophoresis the proteins
were transferred onto nitrocellulose membranes that were
subsequently blocked overnight at 8uC in 5% non-fat milk in
TBS-T buffer (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20;
pH 7.6). The membranes were washed three times in TBS-T for
10 min at RT, and incubated overnight at 8uC with anti-SF2/ASF
antibody (cat. no.: 32–4500, Invitrogen, Carlsbad, Ca) diluted 1:
500 in TBS-T buffer with 5% non-fat milk. After washing 3 times
for 10 min with TBS-T, the membranes were incubated for 1 h at
RT with horseradish peroxidase-conjugated goat anti-mouse
RNA-Splicing in Renal Cancer
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mark), and washed 3 times for 10 min with TBS-T.
Western blotting of hnRNP A1 was performed as for SF2/ASF
analysis using 15 mg of protein extract and anti-hnRNP A1
antibody (cat. no.: ab10685, Abcam plc, Cambridge, UK).
Proteins were detected by an enhanced-chemiluminescence
detection system (Supersignal West Pico Chemiluminescent
Substrate, Pierce Biotechnology, Rockford, IL) according to
standard procedures. Subsequently, the membranes were stripped,
blocked and incubated with anti-b-actin antibody (cat.
no. ab6276, Abcam plc, Cambridge, UK) diluted 1:10000 in
TBS-T buffer for 1 h at RT, washed three times in TBS-T buffer
and further processed as described for SF2/ASF procedure.
The amount of specific protein was estimated densitometrically
after normalization to expression of b-actin.
Prediction of splicing factor binding motifs
Analysis of CEACAM1 exon 7 sequence was performed with
ESE finder software [26]. For the prediction of SF2/ASF binding
sites, two matrices were used: ‘‘SF2/ASF/IgM-BRCA1’’ and
‘‘SF2/ASF’’. These two matrices were derived in different context
(different minigenes and size of random sequence libraries in
SELEX [27]). The thresholds used for prediction were: 1.956
(SF2/ASF), 1.867 (SF2/ASF/IgM-BRCA1), 2.383 (SC35), 2.670
(SRP40), and 2.676 (SRp55). The sequence of exon 7 was derived
from CEACAM1 transcript variant 1 (Acc. no. NM_001712.3).
Statistical analysis
The Shapiro-Wilk test was used to determine normality of data
distribution. Normally distributed data were analyzed by paired t-
test and non-parametric data by Wilcoxon matched pairs test.
p,0.05 was considered statistically significant. Visualization of
correlation matrix was done using corrplot on R platform [28].
Results
The mRNA expression of splicing factors is disturbed in at
least half of ccRCC samples
Splicing factors belonging to the group of SR proteins comprise
a large number of structurally and functionally related proteins
[11]. In our study we focused on the group of ‘‘classical’’ SR
proteins, i.e. SF2/ASF (encoded by gene: SFRS1), SC35 (SFRS2),
Sp20 (SFRS3), SRp75 (SFRS4), SRp40 (SFRS5), SRp55 (SFRS6),
and 9G8 (SFRS7). We have also analyzed expression of a non-SR
splicing factor, hnRNP A1 that is generally believed to act as
antagonist of SR proteins.
Using real-time PCR we found that the pattern of expression of
splicing factors differed between individual patients, as well as
between control and tumor samples of a particular patient. mRNA
expression of all analyzed splicing factors was disturbed in about
50–60% (depending on the splicing factor analyzed) of tumor
samples compared with paired normal tissues (Fig. 1). These
changes of expression were due to down- or upregulation of the
analyzed genes and allowed us to divide all tumor samples into
three pools: D, U, and N in which the expression of genes was
downregulated, upregulated or not changed, respectively. The
direction of changes did not correlate with tumor grade of
differentiation (Fig. 1A).
The number of samples in each pool varied from n=8 for D
and n=14 for U (for hnRNP A1) to n=17 for D and n=4 for U
(for SRp40) (Fig. 2). For majority of samples with altered
expression, pool D was the most abundant (34–45% of all
analyzed samples). The only exception was expression of hnRNP
A1 that was downregulated in only 21% of samples and
upregulated in 37% of all analyzed samples. Downregulation of
genes in pools D varied from 1.9 fold (SRp20) to 2.6 fold (SC35 ad
SRp75) when compared with control samples. Genes in pools U
were upregulated from 1.4 fold (9G8) to 2.4 fold (SF2/ASF) when
compared with control samples.
Quantitative relations between splicing factors differ
between tumor and control samples
In order to explore whether changes in expression of splicing
factors are correlated, we analyzed ratios between expression levels
of splicing factors as well as ratios between specific pairs of splicing
factors (Fig. 3). We found that the pattern of correlations differed
between control and tumor samples, with general tendency for
increased correlation coefficients in tumor samples (Fig. 3A). The
strongest changes in correlation were observed for hnRNP A1. For
instance, there was no significant correlation between hnRNP A1
and SRp20, hnRNP A1 and SRp75, and hnRNP A1 and 9G8 in
control samples, while in tumor samples the expression of these
genes correlated significantly. Also, correlation between SF2/ASF
and the residual six analyzed splicing factors was stronger in tumor
samples.
There are pairs of splicing factors that are known to work
antagonistically [13–15,29]. Therefore we analyzed ratios of the
following specific splicing factors: SF2/ASF: hnRNP A1, SF2/
ASF: SRp20, SF2/ASF: SC35, SRp40: SRp55, SC35: SRp55,
and hnRNP A1: SC35. We found that for the three pairs of
splicing factors the ratios differed significantly in tumor samples
when compared to control samples (Fig. 3B). The SF2/ASF:
hnRNP A1 ratio was decreased in tumor samples by about 26%
(1.0760.06 S.E. for C vs 0.7860.06 S.E. for T; p=0.0022). The
ratio of SC35: SRp55 was increased in tumor samples by about
40% (median 1.12, range 0.60 to 5.91 for C; median 1.57, range
0.59 to 12.29 for T; p=0.0073). For the ratio hnRNP A1: SC35
there was a small (15.3%) but statistically significant increase in
tumors in comparison to control samples (0.7760.05 S.E. for C vs
0.8960.064 S.E. for T; p=0.0197).
The protein expression of SF2/ASF and hnRNP A1 is
disturbed in ccRCC
To check whether changes in mRNA level result in concomitant
disturbances of protein expression we performed Western blot
analysis of two splicing factors, SF2/ASF and hnRNP A1 on twelve
representative pairs of control and tumor samples (Fig. 4). Indeed,
we found significant differences between protein levels of splicing
factors in control and tumor samples. Similarly as in case of mRNA
analysis, the changes were variable but did not correlate with
mRNAexpression.Inmajorityofanalyzed paired tissuesamplesthe
expression of splicing factor was decreased in samples T in
comparison to samples C (SF2/ASF: 9 pairs; hnRNP A1: 8 pairs).
In several samples additional or shifted bands were visible,
especially in blots of SF2/ASF (Fig. 4A). Such a picture is
characteristic for differently phosphorylated molecules of SF2/
ASF protein [30].
Alternative splicing of genes involved in tumorigenesis
and regulated by splicing factors is disturbed in ccRCC
SF2/ASF regulates alternative splicing of a significant number
of genes, including RON proto-oncogene [19], apoptosis regulator
Caspase-9 [22], and Rac1, a member of Ras family of proto-
oncogenes (regulated by SF2/ASF and SRp20) [14]. To
investigate whether alterations in amounts of splicing factors are
followed by changes in alternative processing of target genes, we
analyzed their splicing patterns (Fig. 5). Furthermore, we analyzed
RNA-Splicing in Renal Cancer
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CEACAM1 tumor suppressor [23] whose disturbed splicing is
known to contribute to tumor progression.
We found that levels of different splicing variants of analyzed
genes varied between the majority of the twelve analyzed pairs of
control and tumor samples in which protein level of SF2/ASF and
hnRNP A1 was analyzed (Fig. 5B). Expression of RON proto-
oncogene splice variants Ron and DRon differed between samples
of specific grades of differentiation. In all G3 tumor samples the
ratio DRon/Ron was higher than in paired control samples. In
samples G1 tumor-specific ratio DRon/Ron was higher or similar
in comparison to control samples. In samples taken from patient
number 13 both isoforms were absent in tumor and control
samples. In tumor samples classified as G2 the ratio DRon/Ron
was variable: in two tumor samples it was similar as in paired
controls, in one sample it was higher than in paired control and in
one sample it was lower than in paired control. Splicing patterns of
CEACAM1 did not depend on the differentiation grade of tumor
sample. In seven sample pairs the ratio CEACAM1-S/CEA-
CAM1-L was higher in tumors than in control samples. In two
sample pairs CEACAM1-S was not detected. Splicing pattern of
Rac1 was similar in majority of analyzed samples. The ratio
Rac1b/Rac1 was higher in control samples than in paired tumors
in eleven of analyzed tissue pairs. Seven of analyzed sample pairs
revealed higher ratio of Caspase-9b/Caspase-9a in tumors than in
control samples independently of differentiation grades. Splicing
pattern of GLI1 was the most variable. The ratio of GLI1-FL/
GLI1-DN in seven tumor samples was higher than in paired
controls. In two pairs of samples there were no differences between
ratios of analyzed splice variants; however additional bands were
visible, suggesting presence of not identified splice variants.
In order to find possible connection between changes in
expression of SF2/ASF and splicing of SF2/ASF-regulated genes
we performed Pearson correlation analysis between the expression
of splicing factors and the target exon splicing (Fig. 6). Positive
correlation (r=0.6915, p=0.0127) between Caspase-9a and SF2/
ASF protein was observed in tumor but not in control samples
(r=0.004644, p=0.9886). We also found a positive correlation
(r=0.6187, p=0.0320) between CEACAM1-L and SF2/ASF
protein in tumors but not in control samples (r=0.4482,
p=0.1439). We did not find any correlation between the
expression of SF2/ASF (or hnRNP A1) proteins and the splicing
variants of Ron, Rac1 or GLI-1 (data not shown).
While it is known that SF2/ASF regulates splicing of Caspase-9
[22], there are no data showing that CEACAM1-L is a target of
SF2/ASF or of any other splicing factors. However, it was found
that exon 7 of CEACAM1 contains cis-acting splicing regulatory
elements [23]. Therefore we analyzed the sequence of CEACAM1
exon 7 using matrices for prediction sequences required for
binding of splicing factors SF2/ASF, SC35, SRp40, AND SRp55
Figure 1. Expression of splicing factors mRNA in ccRCC. A. Changes in expression of particular pairs of control and tumor samples. The
diagram was performed based on the data from real-time PCR analysis (Figure S2). Colors represent expression ratio between control and tumor
samples. Green: downregulation in tumor samples. Red: upregulation in tumor samples. White: no difference in expression levels. Tumor grading (G1,
G2, G3) is shown. B. Distribution of changes in mRNA expression of splicing factors. D: group of samples with tumor-specific downregulation of
expression; U: group of samples with tumor-specific upregulation of expression; N: group of samples that did not differ in expression between control
and tumor samples. The threshold of 30% difference in expression between control and tumor samples was used to classify samples.
doi:10.1371/journal.pone.0013690.g001
RNA-Splicing in Renal Cancer
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13690(Fig. 7). This analysis revealed several high-score motifs for SF2/
ASF, two motifs for SC35, three motifs for SRp40, and one motif
for SRP55.
Discussion
In this paper we show that mRNA expression of eight splicing
factors is disturbed in ccRCC. The protein expression of two
splicing factors, known to act antagonistically, SF2/ASF and
hnRNP A1 is also disturbed. These aberrations are accompanied
by impaired alternative splicing of SF2/ASF dependent genes,
RON, Caspase-9, and Rac1. Tumor-specific disturbances of
alternative splicing were also found for GLI1 oncogene and
CEACAM1 tumor suppressor.
Changes in pre-mRNA splicing are a common phenomenon in
human malignancies. According to our findings, improperties in
expression of splicing factors occur in at least half (50–60%) of
analyzed samples, although the disturbances are diverse and result
from both up- and downregulation of splicing factors (Fig. 1 and
2). The direction of changes is not specific for tumor grades of
differentiation since both up- and downregulation were observed
in all gradings. It is notable that although most of the publications
refer to tumor-specific increase of splicing factors expression, the
percentage of samples in which the disturbed expression occurs is
rarely shown. Karni et al. [18] reported that among 50 analyzed
ccRCC samples more than 2-fold overexpression of SF2/ASF
mRNA was observed in less than 5% of samples. According to our
analysis the percentage of samples with more than 2-fold
overexpression was a little higher (8%) but this difference may
result from relatively small number of analyzed samples.
Interestingly, we found that patterns of mRNA and protein
expression of splicing factors differed between individual patients
and also between control and tumor samples of a given patient.
This is in agreement with our previous study showing tumor-
specific and patient-specific splicing patterns of type 1 iodothyr-
onine deiodinase [4] and with other studies, showing that ccRCC
is characterized by molecular heterogeneity and can be separated
into gene expression subgroups [31–33]. In the study of Zhao et al.
[33] those expression subgroups correlated with survival after
surgery but, similarly as in our study, did not correlate with tumor
grades. Unfortunately, in case of our study the patients were not
followed up thus it is not possible to analyze any correlations
between expression profiles and patients survival. Klein et al. [34]
analyzed single residual tumor cells from several types of tumors
Figure 2. Disturbances of expression of splicing factors mRNA. Expression of each splicing factor is shown in two groups of samples: with
tumor-specific downregulation (D) (left) and upregulation (U) (right). The threshold of 30% difference in expression between control and tumor
samples was used to classify samples. C: control samples, T: tumor samples. The data are given as mean 6 S.E.. Statistical analysis was performed
using paired t-test. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0013690.g002
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expression between particular cancer cells. Those cells were
heterogeneous irrespective of whether they resided within the
same compartment or within different homing sites. Patient
specific variation in gene expression was also reported for breast
and prostate cancer [35,36].
Thisgene expression variability is an interesting issue, and at least
two possible origins should be considered: that the variations reflect
the tumor specificity or that they reflect individual patient features
that result in a specific picture of gene expression in tumor. The first
situation was described for liver cancer in which separate tumors
from a single patient showed dramatic differences in gene
expression patterns [37]. On the other hand, Perou et al. [35]
reported that gene expression patterns of different breast tumor
samples taken from one patient were more similar to each other
than to samples taken from other patients. It is not clear which
situation concerns our study as we analyzed single samples per
patient. As we have recently shown, however, ccRCC tumors may
also reveal more homogenous gene expression patterns [6]. In that
study in which we used partially the same material as in this paper,
we found highly consistent ccRCC tumor specific disturbances of
thyroid hormone pathway: decrease of thyroid hormone receptor
b1 (TRb1) mRNA and protein, loss of type 1 iodothyonine
deiodinase protein and lowered level of thyroid hormone,
triiodothyronine (T3). Interestingly, TRb1 protein decrease was
observed in all twelve pairs of tumor and control samples that were
subsequently used for our study. These observations are in
agreement with findings of Takahashi et al., [31] who identified
groups of genes that were similarly or differentially expressed in
ccRCC. Thus, the consistent changes in thyroid hormone pathway
Figure 3. Changes in ratios between splicing factors in tissue samples. A. Matrix showing correlation coefficients between mRNA expression
of analyzed splicing factors. The plot was generated based on Pearson correlation coefficients between expression values of splicing factors. Patient
number 16 was removed from analysis due to deviation from normal distribution. For SC35 (gene: SFRS2) Spearman nonparametric correlation was
used as data were not normally distributed in this group. The values of Pearson or Spearman r are given below the dot diagram. Splicing factors’ gene
names are shown in brackets. P,0.05 was considered statistically significant. B. mRNA expression ratios of splicing factors known to act
antagonistically. The data are given as mean 6 S.E. (for SF2/ASF: hnRNP A1 and hnRNP A1: SC35) or as median values and 95% CI (for SC35: SRp55 as
data were not normally distributed in this group). Statistical analysis was performed using paired t test (for for SF2/ASF: hnRNP A1 and hnRNP A1:
SC35) or Wilcoxon paired test (for SC35: SRp55). n=37 for C, n=37 for T, ** p,0.01.
doi:10.1371/journal.pone.0013690.g003
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while different gene expression patterns of splicing factors may
reflect later events in tumor growth, including mutations as well as
epigenetic and chromosomal alterations.
We observed increase of Pearson coefficients between mRNA
expression of splicing factors in tumors (Fig. 3). These positive
correlations were observed in tumors collected from different
patients and confirmed that the observed changes in expression
result from cancer specific disturbances in tumor tissue and not
from individual differences between patients. Coordinated changes
in expression of splicing factors may suggest the existence of not
yet identified factor that affects the expression of the whole group
of genes involved in splicing. Our observations are consistent with
findings of Warrenfeltz et al. [38] who found that functionally
related genes displayed correlated changes of expression in ovarian
cancer. The coordinated changes of gene expression may result
from several causes. Genes that are located in similar regions of
chromatin may be concomitantly influenced by changes in
chromatin structure or by changes in chromosome regions. The
majority of genes analyzed in our study is located on different
chromosomes (apart from SFRS1 and SFRS2 that are located on
chromosome 17), thus this effect is rather not responsible for the
observed changes. Another reason could be the changed activity of
a transcription factor that regulates expression of analyzed splicing
factors. Such co-regulation of several splicing factors by one factor
is possible, as shown by Mole et al. [39], who discovered that
expression of SF2/ASF, SC35 and SRp75 is upregulated by
human papillomavirus HPV16 infection, possibly via activation of
transcription, controlled by the viral transcription factor E2. There
are known transcription factors whose expression is changed in
ccRCC [6,40], however the question whether they are also
regulators of splicing factors remains for further investigation.
Figure 4. Protein expression of splicing factors in twelve representative pairs of control (C) and tumor (T) samples. Tumor grades of
differentiation are shown (G1, G2, G3). Western blots of SF2/ASF (A) and hnRNP A1 (B) were used for semiquantitative analysis of protein bands after
normalization to b-actin. Gray bars represent control samples. Black bars represent tumor samples.
doi:10.1371/journal.pone.0013690.g004
RNA-Splicing in Renal Cancer
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13690The relative amounts of SR- and non-SR splicing factors, such
as hnRNP A1, may determine patterns of alternative splicing of
many genes. We found that relative amounts of pairs of splicing
factors that are known to act antagonistically statistically
significant differed in tumors in comparison to paired control
samples. This was especially visible for antagonistic pair SF2/ASF
and hnRNP A1 whose ratio is known to influence 59 splice site
selection [13]. When the level of hnRNP A1 is higher than of SF2/
ASF, distal 59 splice site is preferred. In our work the ratio SF2/
ASF: hnRNP A1 was significantly lowered in ccRCC samples in
comparison to controls (Fig. 3B). This result is in agreement with
our previous analysis [4] in which the predominant variants of
type 1 iodothyronine deiodinase (DIO1) found in ccRCC were
those resulting from distal 59 splice site usage.
Apart from disturbed expression, several other factors may also
contributeto improperties infunctionality of splicing factors.One of
them could be disturbed protein phosphorylation, the modification
which determines activity of splicing factors [41]. Of note, Western
blot analysis of SF2/ASF and hnRNP A1 revealed additional or
shifted bands that are characteristic for differently phosphorylated
proteins[30].Oneofkinasespathway thatregulatephosphorylation
of splicing factors is PI3K/Akt [42]. Interestingly, this pathway is
disturbed in ccRCC [43] and thus may possibly contribute to
impaired activity of splicing factors. To confirm, however, that
phosphorylation of splicing factors is disturbed in ccRCC, further
analysis is needed. Another posttranslational modification affecting
the activity of splicing factors is poly(ADP-ribosyl)ation [44–46].
There are no direct data showing changes in poly(ADP-ribose)
polymerase activity in ccRCC; it was shown, however, that
nephrocarcinogens induce poly(ADP-ribosyl)ation of renal proteins
[47]. There are also other modifications that may affect the activity
of splicing factors such as sumoylation [48], and arginine
methylation [49,50]; however further studies are needed to reveal
whether they play any role in ccRCC pathology.
Figure 5. Alternative splicing of genes involved in tumor progression. A. PCR analysis of alternative splicing patterns in twelve pairs of
control (C) and tumor (T) tissue samples. 1) RON; 2) CEACAM-1; 3) Rac1; 4) Caspase-9; 5) GLI1. Positions of primers used for PCR are shown relative to
exons. Alternatively spliced exons are shaded. Gradings of tumor differentiation are shown (G1, G2, G3). B. Graph showing expression ratios of splice
variants as determined by densitometric analysis of electrophoresed PCR products. Note different axis scales. Gray bars represent control samples.
Black bars represent tumor samples.
doi:10.1371/journal.pone.0013690.g005
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tumorigenesis due to synthesis of alternative products that exert
tumor growth promoting activities [51]. Splicing factors themselves
may also act as proto-oncogenes, as it was shown for SF2/ASF [18].
The complex changes of eight splicing factors in ccRCC samples
foundinourwork maythus result inalterationsofsplicingreactions.
Indeed, we show here that alternative splicing of five genes is
disturbed in analyzed tumor tissues. Importantly, these genes are
known to influence the process of tumorigenesis. We found a
positive correlation between Caspase-9a and SF2/ASF protein in
tumor but not in control samples. Similar positive correlation was
found between CEACAM1-L and SF2/ASF protein (Fig. 6.).
Positive correlation between expression of SF2/ASF and Caspase-
9a is in agreement with the observation that SF2/ASF enhances the
expression of Caspase-9a isoform [22]. Lack of correlation between
Caspase-9a/9b ratio suggests that additional factors may influence
the splicing of Caspase-9 as for instance selective degradation of
splice variant 9b or regulatory effect of other proteins. It was shown
that splicing of Caspase-9 is affected by E2F1 and SC35 [52].
Interestingly, as we showed, the expression of E2F1 is disturbed in
ccRCC [53]. The observation that the expression of SF2/ASF and
Caspase-9a correlates positively in tumorous but not in control
samples may possibly suggest that while in non-cancerous kidney
tissues the splicing of Caspase-9 is affected by multiple different
factors (for instance, by E2F1 and SC35),in cancer tissues SF2/ASF
may play the main role.
The pathway of programmed cell death is disturbed in ccRCC
due to loss of apoptosis inducers [54] or upregulation of apoptosis
inhibitors [55]. Our results showing changed ratios of proapoptotic
[9a] and antiapoptotic [9b] Caspase-9 splice variants in tumor
tissue samples resemble those found for survivin, a member of the
inhibitor of apoptosis protein (IAP) family [9]. Mahotka et al. [9]
analyzed survivin splice variants that showed different antiapop-
totic properties and found that the mRNA ratio between survivin-
2B (the isoform lacking antiapoptotic activity) and survivin is
decreased in late tumor stages of ccRCC. Disturbances of
apoptotic pathway are also confirmed in this study, showing
imbalanced ratios of GLI1 variants. GLI1 is a transcription factor
of oncogenic potential [56] that increases expression of a number
of antiapoptotic factors. Moreover, it was shown that GLI1
mRNA expression is upregulated in ccRCC [57]. Together these
results suggest that ccRCC specific disturbances of apoptosis may
result not only from general changes of levels of apoptotic
regulators but also from perturbations of alternative splicing.
Figure 6. Correlation between protein expression of SF2/ASF and Caspase-9a (A) and CEACAM1-L (B). Pearson correlation analysis was
performed on data from twelve pairs of control and tumor tissue samples. P,0.05 was considered statistically significant.
doi:10.1371/journal.pone.0013690.g006
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effects on cancerous growth and invasion [58]. It affects cell
adhesion, apoptosis, morphogenesis, cell proliferation, invasion,
cell migration, angiogenesis, lymphangiogenesis and cytotoxicity.
The activity of CEACAM1 is regulated by alternative splicing that
generates two types of cytoplasmic domain: short (present in
CEACAM1-S isoform) and long (present in CEACAM1-L) one.
Both CEACAM1-L and CEACAM1-S were shown to inhibit
tumor growth when transfected and expressed in different types of
cancer [59–61]. It was suggested that the ratio of S: L isoforms
may define suppressive properties of particular isoforms [23] and
that CEACAM1-L activity may be inhibited by CEACAM1-S
[62]. Our results showing increased S:L ratio in tumor cells are
consistent with antagonistic properties of the two CEACAM1
isoforms. Interestingly, Kammerer et al. [63] found that
CEACAM1 protein is completely lost in ccRCC; however, this
group did not analyze CEACAM1 mRNA level or splicing
patterns in cancer tissues. There are no data showing that
CEACAM1-L is a target of SF2/ASF or any other splicing factor
analyzed in our study. However, Gaur et al. [23] identified cis-
acting splicing regulatory elements located in exon 7 of
CEACAM1. Analysis of CEACAM1 exon 7 revealed several
high-score motifs for SF2/ASF, SC35, SRp40, and SRP55 (Fig. 7).
Although a score above threshold does not necessarily mean that
the sequence functions as an exonic splicing enhancer, these results
together with positive correlation between the level of CEA-
CAM1-L and SF2/ASF and the presence of regulatory cis acting
elements in CEACAM1 exon 7 suggest that SF2/ASF may play a
regulatory role in CEACAM1 splicing. This issue needs further
confirmation by experimental data showing direct binding
between CEACAM1 exon 7 and SF2/ASF.
We did not find any correlation between SF2/ASF (or hnRNP
A1) and the splicing pattern of Ron, Rac1 or GLI-1 which may
possibly suggest that other factors may play a role in regulation of
these genes’ splicing. RON tyrosine kinase is a proto-oncogene
that controls invasive growth of tumors [64]. Alternatively spliced
isoforms of RON found in cancers promote changes in tumor cell
morphology, stimulate proliferation and abrogate cell-cell adhe-
sion [19,65]. RON dependent cell motility is regulated by SF2/
ASF that controls alternative splicing of this protooncogene [19].
It was shown that ccRCC tumors classified as G3 and G2
differentiation grades have higher metastasis rates compared to
Figure 7. Analysis of CEACAM1 exon 7 sequence in a search for potential binding motifs of splicing factors. Prediction of motifs was
performed with ESE Finder software [26] using matrices for prediction of sequences required for binding of splicing factors. For the prediction of SF2/
ASF binding sites, two matrices were used: ‘‘SF2/ASF/IgM-BRCA1‘‘ (white bars) and ‘‘SF2/ASF‘‘ (gray bars). These two matrices were derived in
different context (different minigenes and size of random sequence libraries in SELEX [27]). Only high-score motifs above thresholds for SF2/ASF
(1.956), SF2/ASF/IgM-BRCA1 (1.867), SC35 (2.383), SRP40 (2.670), and SRp55 (2.676) are shown. The nucleotide sequence of CEACAM1 exon 7 is given
on x-axis.
doi:10.1371/journal.pone.0013690.g007
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that triggers invasive tumor growth and whose accumulation is
observed in colon and breast cancers [19,67], our results showing
higher tumor-specific DRON/RON ratio in all tumor samples
classified as G3 grade are in line with those observations.
Rac1 is a member of Rho-like GTPases that affect changes in actin
cytoskeleton and regulate cell adhesion, migration and invasion [68].
Alternative splicing regulates cancer-related properties of Rac1,
leading to synthesisof constitutively active Rac1b, whose expression is
upregulated in cancers [24]. Moreover, Rac1b expression in NIH-
3T3 cells causes growth transformation [69] and determines survival
of colon cancer cells [70]. Our results showing that ratio of Rac1b:
Rac1 is higher in controls than in ccRCC samples suggest that this
isoform rather does not play tumor promoting role in ccRCC. This is
in line with previous findings of Engers et al. [71] who showed that
forced expression of Rac1 in ccRCC cells leads to inhibition of cell
migration and invasion. This group, however, did not look at the
splicing profile of Rac1, therefore the exact role of Rac1b in ccRCC
remains for further investigations.
In conclusion, we show that changes in expression of splicing
factors belonging to SR proteins family and a non-SR protein,
hnRNP A1, may possibly lead to disturbances of alternative
splicing in ccRCC. These disturbances may potentially be directly
connected with tumor progression as they result in impaired
alternative splicing of genes involved in apoptosis, and cell
adhesion. We suggest that changes in correlation between
expression levels of splicing factors may potentially serve as
markers of carcinogenesis in ccRCC and that splicing factors may
possibly constitute therapeutic targets in patients with disturbed
expression of specific splicing regulators. This last possibility was
already successfully tested on cancer cell lines by Patry et al. [72].
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